EU Health Data Access Proposal Should Not Include Opt-Out Model, Pharma Says
The European Commission is mulling the addition of an opt-out mechanism for patients under its European Health Data Space framework, but health and pharma industry stakeholders have warned that this could cause “scientific damage” and act as a barrier to research.
You may also be interested in...
The medtech industry is set to benefit from access to large amounts of patient health data under the proposed European Health Data Space, but a new report reveals that EU citizens would like more control in how their data are used.
Protection of IP and trade secrets and the need for clarity around issues such as the rules on access to data and the sharing of clinical trial data are seen as key issues in the European Commission’s plans for a European Health Data Space.
Convincing payers to fund a $3m therapy is no mean feat, even for innovations with curative potential. Orchard Therapeutics, a company with much experience in this field, tells the Pink Sheet why it values open dialogues, and outlines how health technology assessment methods could be improved.